Skip to main content
. 2016 Oct 18;7(47):77622–77634. doi: 10.18632/oncotarget.12731

Figure 4. The dose-dependent analysis of caspase-3 activity and the expression of apoptosis-associated proteins in bortezomib-resistant HCC cells and their parental cells.

Figure 4

A. Wild-type HepG2, HepG2/BTZ, wild-type HuH7, and HuH7/BTZ cells were treated with various concentrations of bortezomib for 48 h. Apoptosis was then measured by cell viability and caspase-3 activity. **: P<0.01; *: P<0.05 as compared with the respective control. Data are the mean ± SD of three independent experiments. B. Wild-type HepG2, HepG2/BTZ, wild-type HuH7, and HuH7/BTZ cells were treated with various concentrations of bortezomib for 48 h. Expression levels of cleaved PARP, cleaved caspase-3, and β-actin (loading control) were evaluated by western blot analyses. BTZ, bortezomib.